Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
about
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaNovel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Targeting CD22 in B-cell malignancies: current status and clinical outlook.The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
P2860
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@en
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@nl
type
label
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@en
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@nl
prefLabel
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@en
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@nl
P2093
P2860
P1476
Dose, timing, schedule, and th ...... ing human lymphoma xenografts.
@en
P2093
David Pearson
Hayes C McKnight
Joseph M Tuscano
Robert T O'Donnell
Yunpeng Ma
P2860
P2888
P304
P356
10.1007/S00262-009-0713-8
P577
2009-05-13T00:00:00Z